Table 3. Characteristics of the SARS-CoV-2 IgG positive population.
| Studied population | Tested for Chikungunya (n = 7,349) | Tested for Dengue (n = 1,700) | Total Patients (n = 7,370) | |||
|---|---|---|---|---|---|---|
| Presence of anti-SARS-CoV2 IgG* (%) | 176 (2.39%) | 85 (5.00%) | 210 (2.85%) | |||
| Patients positive for SARS-CoV2 and arboviruses** (%) | 68 (38.63%) | 11 (12.94%) | 79 (37.62%) | |||
| Immunoreactivity/Gender | Female | Male | Female | Male | Female | Male |
| Gender (%) | 49 (72.1%) | 19 (27.9%) | 7 (63.6%) | 4 (36.4%) | 133 (63.3%) | 77 (36.7%) |
| Age (years) Average ± S.D. | 43.7 ± 14.1 | 50.5 ± 13.2 | 45.6 ± 12.6 | 38.3 ± 12.6 | 44.4 ± 17.3 | 46.0 ± 14.8 |
| Anti-SARS-CoV2 IgG Positive Titer (Average ± SD) | 5.0 ± 3.5 | 5.4 ± 3.3 | 4.8 ± 1.9 | 2.9 ± 2.0 | 4.2 ± 2.0 | 3.8 ± 1.8 |
| Dengue or Chikungunya Specific IgM titer (DO/CO) Average ± SD | 6.5 ± 3.0 | 6.1 ± 2.9 | 2.1 ± 1.9 | 2.1 ± 1.1 | N.A. | N.A. |
*—Compared to the number of either Chikungunya (n = 7,349), Dengue. (n = 1,700) or Total samples tested (n = 7,370)
**—Compared to the total number of SARS-CoV2 IgG positive samples Chikungunya (n = 176), Dengue. (n = 85) or Total groups (n = 210).
N.A.–Not applicable.